These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27790016)

  • 1. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation.
    Townes SV; Furst DE; Thenkondar A
    Open Access Rheumatol; 2012; 4():87-92. PubMed ID: 27790016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ
    Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.
    Singh JA; Beg S; Lopez-Olivo MA
    J Rheumatol; 2011 Jan; 38(1):10-20. PubMed ID: 20952462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab.
    Fusama M; Nakahara H; Hamano Y; Nishide M; Kawamoto K; Hosokawa T; Nozato S; Higa S; Igarashi T; Takeuchi E; Kuroiwa T; Shimaoka Y; Yukioka M; Miura Y; Higashi K; Kuritani T; Maeda K
    Mod Rheumatol; 2013 Mar; 23(2):276-83. PubMed ID: 22669600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for rheumatoid arthritis.
    Singh JA; Beg S; Lopez-Olivo MA
    Cochrane Database Syst Rev; 2010 Jul; (7):CD008331. PubMed ID: 20614469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.
    Fragiadaki K; Tektonidou MG; Konsta M; Chrousos GP; Sfikakis PP
    J Rheumatol; 2012 Jan; 39(1):60-2. PubMed ID: 22133618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis.
    Wells G; Li T; Maxwell L; MacLean R; Tugwell P
    J Rheumatol; 2007 Feb; 34(2):280-9. PubMed ID: 17304654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.
    Campbell L; Chen C; Bhagat SS; Parker RA; Östör AJ
    Rheumatology (Oxford); 2011 Mar; 50(3):552-62. PubMed ID: 21078627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between Sleep Disorders, Pain and Quality of Life in Patients with Rheumatoid Arthritis.
    Purabdollah M; Lakdizaji S; Rahmani A; Hajalilu M; Ansarin K
    J Caring Sci; 2015; 4(3):233-41. PubMed ID: 26464840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis.
    Plushner SL
    Ann Pharmacother; 2008 Nov; 42(11):1660-8. PubMed ID: 18957621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.